SuperworthRani Therapeutics RANI
- Market cap
- $84.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 17.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.9M
- growth n/m, growth from a base too small to compare
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −24.1%
Rani Therapeutics trades at 17.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.9M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | $0 | $0 | $0 | $1M | $172K | $0 | $0 | $1.5M+42% | $1.7M+893% | $1.7M | |
| R&D | $11.2M+23% | $7.6M−27% | $7.6M−22% | $6.1M−45% | $6.2M−45% | $6.8M−11% | $6.6M−13% | $5.5M−10% | $3.2M−48% | $4.9M−28% | $5.2M−21% | $5M−9% |
| SG&A | $6.6M−8% | $5.8M−18% | $6.4M−5% | $6.4M−11% | $5.6M−15% | $5.5M−6% | $5.6M−13% | $5M−22% | $4M−28% | $5.1M−7% | $4.9M−13% | $5.5M+10% |
| −$17.9M+9% | −$13.4M−23% | −$14M−15% | −$12.5M−32% | −$11.8M−34% | −$15M+11% | −$12M−14% | −$10.5M−16% | −$7.3M−39% | −$8.5M−43% | −$8.3M−31% | −$8.8M−16% | |
| Interest expense | $1.3M+274% | $1.3M+80% | $1.3M+7% | $1.3M+1% | $1.3M+2% | $1.1M−13% | $943K−27% | $877K−31% | $725K−46% | $347K−69% | $88K−91% | $8K−99% |
| Pre-tax income | −$18.3M+12% | −$14.1M−19% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$9.2M+16% | −$7.1M−19% | −$7.5M−11% | −$6.8M−27% | −$6.8M−26% | −$8.9M+26% | −$7.3M−3% | −$6.7M−2% | −$5.4M−20% | −$10.3M+15% | −$7M−3% | −$7.4M+10% |
| −$0.36 | −$0.27−23% | −$0.29−12% | −$0.26−30% | −$0.24−33% | −$0.27+0% | −$0.22−24% | −$0.18−31% | −$0.12−50% | −$0.07−74% | −$0.04−82% | −$0.04−78% | |
| 25.6M+4% | 25.9M+4% | 26M+3% | 26.3M+4% | 28.8M+13% | 32.7M+26% | 33.4M+28% | 36.5M+39% | 46.4M+61% | 147.1M+350% | 180M+438% | 187.2M+412% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20 and Q1 FY21: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Rani Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RANIRani Therapeutics | $84.5M | n/m | n/a | 17.3× | n/m | n/m | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Rani Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .